118 related articles for article (PubMed ID: 19259288)
1. Irinotecan-induced dysarthria: an insight into its pathogenesis?
Gomez JA; Sanchez I; Ramirez JA
Gastrointest Cancer Res; 2008 Jul; 2(4):209-10. PubMed ID: 19259288
[No Abstract] [Full Text] [Related]
2. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review.
De Lisa M; Ballatore Z; Marcantognini G; Pierantoni C; Antognoli S; Pistelli M; Pagliacci A; Berardi R
Oncol Ther; 2020 Jun; 8(1):147-160. PubMed ID: 32700070
[TBL] [Abstract][Full Text] [Related]
3. Dysarthria induced by irinotecan in a patient with colorectal cancer.
Lee KA; Kang HW; Ahn JH; Suk HJ; Kim H
Am J Health Syst Pharm; 2013 Jul; 70(13):1140-3. PubMed ID: 23784161
[TBL] [Abstract][Full Text] [Related]
4. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.
Zhen DB; McDevitt RL; Zalupski MM; Sahai V
J Oncol Pharm Pract; 2019 Jun; 25(4):980-986. PubMed ID: 29562843
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-induced dysarthria: A case report and review of the literature.
Ramirez KG; Koch MD; Edenfield WJ
J Oncol Pharm Pract; 2017 Apr; 23(3):226-230. PubMed ID: 26911479
[TBL] [Abstract][Full Text] [Related]
7. [Dysarthria during irinotecan administration].
Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
[No Abstract] [Full Text] [Related]
8. Irinotecan-induced dysarthria.
Baz DV; Bofill JS; Nogueira JA
J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
[No Abstract] [Full Text] [Related]
9. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
[No Abstract] [Full Text] [Related]
10. FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.
Matsuoka A; Maeda O; Inada-Inoue M; Ohno E; Hirooka Y; Yokoyama Y; Fujii T; Nagino M; Goto H; Ando Y
Oncol Lett; 2015 Oct; 10(4):2662-2664. PubMed ID: 26622908
[TBL] [Abstract][Full Text] [Related]
11. A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Joseph R; Dasanu CA
J Oncol Pharm Pract; 2014 Oct; 20(5):393-6. PubMed ID: 24103898
[TBL] [Abstract][Full Text] [Related]
12. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.
Lima-Júnior RC; Figueiredo AA; Freitas HC; Melo ML; Wong DV; Leite CA; Medeiros RP; Marques-Neto RD; Vale ML; Brito GA; Oriá RB; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):931-42. PubMed ID: 22101361
[TBL] [Abstract][Full Text] [Related]
13. The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Wong DV; Lima-Júnior RC; Carvalho CB; Borges VF; Wanderley CW; Bem AX; Leite CA; Teixeira MA; Batista GL; Silva RL; Cunha TM; Brito GA; Almeida PR; Cunha FQ; Ribeiro RA
PLoS One; 2015; 10(10):e0139985. PubMed ID: 26440613
[TBL] [Abstract][Full Text] [Related]
14. Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy.
Chandar M; de Wilton Marsh R
Case Rep Oncol; 2015; 8(1):138-41. PubMed ID: 25873880
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Ribeiro RA; Wanderley CW; Wong DV; Mota JM; Leite CA; Souza MH; Cunha FQ; Lima-Júnior RC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):881-893. PubMed ID: 27590709
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Hamberg P; De Jong FA; Brandsma D; Verweij J; Sleijfer S
Acta Oncol; 2008; 47(5):974-8. PubMed ID: 17924208
[No Abstract] [Full Text] [Related]
17. Dysarthria and lacunar stroke: pathophysiologic aspects.
Urban PP; Hopf HC; Zorowka PG; Fleischer S; Andreas J
Neurology; 1996 Nov; 47(5):1135-41. PubMed ID: 8909418
[TBL] [Abstract][Full Text] [Related]
18. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.
Gao K; Lockwood WW; Li J; Lam W; Li G
Int J Oncol; 2008 Jun; 32(6):1343-9. PubMed ID: 18497997
[TBL] [Abstract][Full Text] [Related]
19. Dysphagia and dysarthria in myasthenia gravis.
WALANDER A
Acta Otolaryngol; 1959; 50(3-4):361-4. PubMed ID: 13660797
[No Abstract] [Full Text] [Related]
20. Management of non-progressive dysarthria: practice patterns of speech and language therapists in the Republic of Ireland.
Conway A; Walshe M
Int J Lang Commun Disord; 2015; 50(3):374-88. PubMed ID: 25652223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
